bioMerieux S.A.

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
  • TickerBIM
  • ISINFR0013280286
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Christophe-Raphaël Ganet

bioMerieux : BioMérieux increases its holding in Hybiome Biomedical

>BioMérieux increases its holding in Hybiome from 54% to 67% - In a press release this morning, bioMérieux has announced that it is increasing its stake in Hybiome Biomedical by 13% (for around € 20m, according to the press release) to 67%. Hybiome is a Chinese company that markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome generated robust sal...

Christophe-Raphaël Ganet

bioMerieux : BioMérieux increases its holding in Hybiome Biomedical

>BioMérieux increases its holding in Hybiome from 54% to 67% - In a press release this morning, bioMérieux has announced that it is increasing its stake in Hybiome Biomedical by 13% (for around € 20m, according to the press release) to 67%. Hybiome is a Chinese company that markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome generated robust sal...

Christophe-Raphaël Ganet

bioMérieux : bioMérieux annonce augmenter sa participation dans la société Hybiome Biomedical

>Augmentation de 13% de sa participation pour atteindre 67% du capital - Dans un communiqué ce matin, bioMérieux a annoncé augmenter sa participation de 13% (réalisée pour environ 20 M€ selon le communiqué) pour atteindre désormais 67% du capital d’Hybiome. Pour rappel, Hybiome est une société chinoise spécialisée dans les tests d’immunoessais automatisés avec 2 plateformes automatisées de moyenne cadence (AE-180 et AE-240) qui utilisent une technologie CLIA1 de derni...

Michael Waterhouse

Morningstar | Dropping Coverage of BioMerieux

We are dropping coverage of BioMerieux. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of BioMerieux later in the year.

Michael Waterhouse

Dropping Coverage of BioMerieux

We are dropping coverage of BioMerieux. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing. We expect to reinitiate coverage of BioMerieux later in the year. ...

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - BIOMERIEUX : Faux départ au T1, objectifs 2019 réitérés - VENTE, OC 59€ (vs 57€)

1 director sold

A director at Biomerieux sold 8,000 shares at 73.514EUR and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Alfred Glaser ...
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Jerôme Bodin
  • Laurence Hofmann
  • Martial Descoutures
  • Michael Foundoukidis
  • Pierre Tegner
  • Pierre Corby
  • Roland Pfaender
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 24/04/2019

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/19/2019

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Roland Pfaender
  • Samantha Jeary
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/03/2019

...

Alain William ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Louis Boujard
  • Philippe Ourpatian
  • Pierre Tegner
  • Rémi Adam
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/27/2019

This is the thirteenth update of our report on Corporate Governance large caps Europe. We have analysed 125 of the European companies covered by ODDO BHF analysts. In the Strong opportunities (1), we favour five stocks: Unibail Rodamco (Buy, target price € 190.0), AXA (Buy, target price € 28.0), Veolia (Buy, target price € 30.0), Danone (Buy, target price € 81.0) and Michelin (Buy, target price € 130.0). - Cf. report published today. - ...

Alain William ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Louis Boujard
  • Philippe Ourpatian
  • Pierre Tegner
  • Rémi Adam
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 27/02/2019

13ème mise à jour de notre étude Corporate Governance Large caps Europe. Nous avons étudié 125 valeurs, toutes suivies par les analystes d’Oddo BHF. Nous privilégions 5 valeurs dans les opportunités fortes : Unibail Rodamco (Achat, OC 190.0 €), AXA (Achat, OC 28.0 €), Veolia (Achat, 30.0 €), Danone (Achat, 81.0 €) et Michelin (Achat, 130.0 €). Cf. étude publiée ce matin. - ...

BIOMERIEUX SA sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to BIOMERIEUX SA (FR), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date January 15, 2019, the closing price was EUR 58.50 and its target price was estimated at EUR 51.22.

MarketLine Department

Bio-Rad Laboratories, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Bio-Rad Laboratories, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Bio-Rad Laboratories, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

MarketLine Department

Great Basin Scientific Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Great Basin Scientific Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Great Basin Scientific Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

Charles Pinel

Biomérieux - Assemblée générale des actionnaires du 23 mai 2019

Il convient de féliciter la société qui propose l'approbation des différentes nouvelles conventions réglementées dans des résolutions spécifiques, ce qui permet aux actionnaires de les approuver de façon séparée. En revanche, il est regrettable que les conventions anciennes qui se poursuivent ne soient pas soumises à l'approbation des actionnaires (résolutions 5 à 7). Le nombre de membres du conseil passera de 11 à 9 à l'issue de l'assemblée générale. Bien que la famille Mérieux n'y détienne qu'un seul siège alors qu'elle possède 59% du capital, il demeure composé d'une majorité de membres no...

Expert Corporate Governance Service (ECGS)

BioMérieux - AGM and EGM 23 May 2019

ITEMS 5 to 7: The Company seeks shareholder approval of various new regulated agreements. ECGS notes that these agreements are in separate resolutions, which allows shareholders to vote on each one of them. However, we regret that the previous agreements that are still ongoing, are not subject to shareholder approval.  ITEM 9: After the Annual General Meeting, the number of Board members will be decreased from 11 to 9. Although the Mérieux family holds 59% of the capital and the board will still be composed by a majority of members that are not considered independent. This leads ECGS to OPPOS...

Proxy Report - 17/05/2018

La fin de l'exercice 2017 fût marquée par la nomination d'Alexandre Mérieux, ancien Directeur Général Délégué de la société, en qualité de Président-Directeur Général pour succéder à Jean-Luc Bélingard. Il est regrettable que la société n'ait pas profité de ce changement au sein de la direction pour séparer les fonctions de Président et de Directeur Général. Cette année encore, Proxinvest ne soutiendra pas la rémunération attribuée à Jean-Luc Bélingard et Alexandre Mérieux pour des raisons similaires à l'année dernière (Résolution 10 et 11) : une rémunération différée revue à la hausse sur la...

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 70,40 € prochainement. Le prochain objectif est à 63,02 €, puis 58,70 €. Le franchissement de 74,56 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - BIOMERIEUX : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €70.40. The next target is at €63.02, then €58.70. Passing €74.56 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - BIOMERIEUX : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 63,02 €. La tendance baissière serait remise en cause au-dessus de 74,56 €.

Jérôme VINERIER

Short term view - BIOMERIEUX : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €63.02. The bearish trend would be challenged above €74.56.

Jérôme VINERIER

Analyse moyen terme - BIOMERIEUX : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch